Shareholders of Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights - SRPT

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1] Group 1: Allegations - The complaint alleges that Sarepta Therapeutics made materially false and misleading statements about ELEVIDYS, a gene therapy for Duchenne muscular dystrophy, which posed significant safety risks to patients [1] - It is claimed that the trial protocols for ELEVIDYS failed to detect severe side effects, leading to potential regulatory scrutiny and halting of recruitment and dosing in trials [1] - The severity of adverse events from ELEVIDYS treatment is said to have misled investors regarding the therapy's approval prospects and overall safety [1] Group 2: Class Action Details - The class period for the lawsuit is defined as June 22, 2023, to June 24, 2025, and shareholders are encouraged to register for participation [2] - The deadline for shareholders to seek lead plaintiff status is August 25, 2025, with no cost or obligation to participate in the case [2] Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3] - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3]